Chemomab Therapeutics (CMMB) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Chemomab Therapeutics is the larger company by market cap ($10.1 million vs $9.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CMMB | MTVA |
|---|---|---|
| Share price | $1.38 | $1.39 |
| Market cap | $10.09M | $9.16M |
| 1-day change | +1.27% | -4.80% |
| YTD return | -16.97% | — |
| 1-year return | -60.69% | — |
| 5-year return | -96.23% | — |
| EPS (TTM) | $-1.04 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $14.85 |
| 52-week low | $1.05 | $0.966 |
| Distance from 52-week high | -61.20% | -90.64% |
| Average volume | 118.53K | 230.88K |
| Shares outstanding | 7.33M | 6.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CMMB vs MTVA FAQ
Which is bigger, Chemomab Therapeutics or MetaVia?
Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $10.09M compared with $9.16M for MetaVia (MTVA).
Are Chemomab Therapeutics and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.